Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Journal of Clinical Oncology.
Times cited: 1042
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B study 8662.
Clinical Cancer Research.
Times cited: 92
A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B.
Journal of immunotherapy (Hagerstown, Md. : 1997).
Times cited: 17